title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
"Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board - Climb Bio  ( NASDAQ:CLYM ) ",20241111T120000,https://www.benzinga.com/pressreleases/24/11/g41875065/climb-bio-appoints-douglas-e-williams-ph-d-as-chair-of-the-board,BMY,0.055881,Neutral,-0.043982
"Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board",20241111T120000,https://www.globenewswire.com/news-release/2024/11/11/2978194/0/en/Climb-Bio-Appoints-Douglas-E-Williams-Ph-D-as-Chair-of-the-Board.html,BMY,0.033468,Neutral,-0.042717
"Researchers return to Alzheimer's vaccines, buoyed by recent drug success",20231120T111500,https://www.reuters.com/business/healthcare-pharmaceuticals/researchers-return-alzheimers-vaccines-buoyed-by-recent-drug-success-2023-11-20/,BMY,0.041682,Neutral,0.0
"Stablix Appoints Douglas Williams, Ph.D., to Board of Directors",20230118T120047,https://www.benzinga.com/pressreleases/23/01/g30458105/stablix-appoints-douglas-williams-ph-d-to-board-of-directors,BMY,0.063425,Neutral,-0.038049
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win - Biogen  ( NASDAQ:BIIB ) ,20220928T201722,https://www.benzinga.com/general/biotech/22/09/29061026/these-stocks-are-on-the-radar-after-biogen-eisais-surprising-alzheimers-trial-win,BMY,0.112269,Neutral,0.0
ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer,20240122T130000,https://www.prnewswire.com/news-releases/immunobrain-checkpoint-appoints-dr-sanjay-keswani-as-chief-executive-officer-302039635.html,BMY,0.065685,Neutral,0.085332
"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight",20231122T220100,https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html,BMY,0.052656,Neutral,0.017928
"Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update",20220815T110000,https://www.globenewswire.com/news-release/2022/08/15/2498065/0/en/Pyxis-Oncology-Reports-Financial-Results-for-the-Second-Quarter-Ended-June-30-2022-and-Provides-Pipeline-Update.html,BMY,0.024597,Neutral,-0.011764
68 Biggest Movers From Yesterday,20220419T083535,https://www.benzinga.com/news/22/04/26681653/68-biggest-movers-from-yesterday,BMY,0.02852,Neutral,0.006314
Stock Market Holds On To Gains; Nvidia Stock Lifts As Earnings Loom,20231120T160300,https://www.investors.com/market-trend/stock-market-today/stock-market-pulls-ahead-to-start-holiday-week-boeing-leads-the-dow/,BMY,0.09347,Neutral,-0.072683
"Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight",20240409T214100,https://www.prnewswire.com/news-releases/global-tissue-banking-market-to-exhibit-growth-at-a-considerable-cagr-of-6-by-2030-assesses-delveinsight-302110459.html,BMY,0.045962,Neutral,0.044896
"Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts DelveInsight",20240124T220100,https://www.prnewswire.com/news-releases/drug-eluting-balloons-global-market-is-expected-to-expand-at-a-healthy-growth-rate-of-8-by-2028-predicts-delveinsight-302042856.html,BMY,0.025985,Neutral,0.033663
"Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight",20240115T220500,https://www.prnewswire.com/news-releases/heart-failure-treatment-drug-market-to-accelerate-immensely-by-2032-predicts-delveinsight-302034593.html,BMY,0.093561,Neutral,0.092837
Compass Pathways appoints Teri Loxam as Chief Financial Officer,20231207T124337,https://investingnews.com/compass-pathways-appoints-teri-loxam-as-chief-financial-officer/,BMY,0.032513,Neutral,0.118414
Compass Pathways appoints Teri Loxam as Chief Financial Officer - Compass Pathways  ( NASDAQ:CMPS ) ,20231207T120000,https://www.benzinga.com/pressreleases/23/12/g36130382/compass-pathways-appoints-teri-loxam-as-chief-financial-officer,BMY,0.030759,Neutral,0.117589
Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors,20220519T114357,https://investingnews.com/cardiol-therapeutics-appoints-teri-loxam-and-chris-waddick-to-its-board-of-directors/,BMY,0.028708,Neutral,0.024397
34 Stocks Moving In Monday's Mid-Day Session,20220418T161356,https://www.benzinga.com/news/22/04/26671086/34-stocks-moving-in-mondays-mid-day-session,BMY,0.055377,Neutral,0.001603
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",20231016T115000,https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-301957344.html,BMY,0.044386,Neutral,-0.047896
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",20231016T115000,https://www.newswire.ca/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-816998848.html,BMY,0.044386,Neutral,-0.047896
"Oral Transmucosal Drug Market to Hit USD 27 billion by 2031, at a CAGR 6%| Says Transparency Market Research, Inc.",20240105T113000,https://www.benzinga.com/pressreleases/24/01/g36506871/oral-transmucosal-drug-market-to-hit-usd-27-billion-by-2031-at-a-cagr-6-says-transparency-market-r,BMY,0.034136,Neutral,0.058626
"Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar",20240111T220100,https://www.prnewswire.com/news-releases/gastroenteropancreatic-neuroendocrine-tumors-market-to-showcase-a-significant-growth-by-2032-evaluates-delveinsight--key-players---eli-lilly-and-company-phanes-therapeutics-camurus-ab-advanced-accelerator-applications-pharma-302032286.html,BMY,0.025139,Neutral,0.034515
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period  ( 2019-2032 )  | DelveInsight,20231121T220100,https://www.prnewswire.com/news-releases/colorectal-cancer-treatment-drug-market-to-show-immense-growth-during-the-study-period-20192032--delveinsight-301994315.html,BMY,0.023102,Neutral,-0.093525
"Stocks That Hit 52-Week Lows On Wednesday - Bristol-Myers Squibb Company Common Stock  ( NYSE:BMY ) , SenesTech, Inc. - Common Stock  ( NASDAQ:SNES ) ",20231004T160117,https://www.benzinga.com/markets/options/23/10/35092508/stocks-that-hit-52-week-lows-on-wednesday,BMY,0.025413,Neutral,-0.094732
"Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors",20230327T120000,https://www.prnewswire.com/news-releases/aadi-bioscience-appoints-mohammad-hirmand-md-to-board-of-directors-301781997.html,BMY,0.043579,Neutral,-0.00491
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates,20230228T210100,https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-corporate-updates-301758465.html,BMY,0.021484,Neutral,0.0
"Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo",20231004T210100,https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html,BMY,0.086948,Neutral,-0.040696
"Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 Results - ATN International  ( NASDAQ:ATNI ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",20240425T183233,https://www.benzinga.com/news/earnings/24/04/38441305/crude-oil-moves-higher-bristol-myers-squibb-shares-fall-after-q1-results,BMY,0.180685,Neutral,-0.033345
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",20230803T210100,https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,BMY,0.041466,Neutral,-0.038518
Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board,20220816T123000,https://www.globenewswire.com/news-release/2022/08/16/2499067/0/en/Processa-Pharmaceuticals-Appoints-Khoso-Baluch-and-James-Neal-to-its-Board-of-Directors-and-Justin-Yorke-to-Chairman-of-the-Board.html,BMY,0.046816,Neutral,0.026632
99 Biggest Movers From Yesterday,20220512T082956,https://www.benzinga.com/news/22/05/27156577/99-biggest-movers-from-yesterday,BMY,0.021239,Neutral,0.148796
"Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... - PR Newswire",20231214T221500,https://www.prnewswire.com/news-releases/neuropathy-pain-treatment-market-size-to-grow-by-usd-5-84-billion-from-2023-to-2028--north-america-accounts-for-33-of-market-growth--technavio-302015282.html,BMY,0.078099,Neutral,0.0
Recap Of Friday's Biotech Catalysts - End Of The Day Summary,20220722T215911,https://www.benzinga.com/general/biotech/22/07/28176253/recap-of-fridays-biotech-catalysts-end-of-the-day-summary,BMY,0.138464,Somewhat-Bullish,0.189661
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer,20230911T103000,https://www.globenewswire.com/news-release/2023/09/11/2740616/0/en/SpringWorks-Therapeutics-Appoints-Dr-Tai-An-Lin-as-Chief-Scientific-Officer.html,BMY,0.038717,Neutral,0.010654
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer - SpringWorks Therapeutics  ( NASDAQ:SWTX ) ,20230911T103000,https://www.benzinga.com/pressreleases/23/09/g34432690/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer,BMY,0.037098,Neutral,0.010592
"Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors",20230330T113000,https://www.globenewswire.com/news-release/2023/03/30/2637531/16626/en/Zevra-Therapeutics-Appoints-Biopharma-Veteran-Wendy-Dixon-Ph-D-to-Board-of-Directors.html,BMY,0.066139,Neutral,0.070237
"Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors",20220613T200100,https://www.globenewswire.com/news-release/2022/06/13/2461601/0/en/Iovance-Biotherapeutics-Appoints-Wendy-L-Dixon-Ph-D-to-Board-of-Directors.html,BMY,0.029501,Neutral,0.032284
"Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors",20220613T200100,https://www.benzinga.com/pressreleases/22/06/g27684549/iovance-biotherapeutics-appoints-wendy-l-dixon-ph-d-to-board-of-directors,BMY,0.028285,Neutral,0.032969
"Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... - PR Newswire",20230918T091500,https://www.prnewswire.com/news-releases/breast-cancer-monoclonal-antibodies-market-to-grow-by-usd-15-billion-from-2022-to-2027-north-america-to-account-for-42-of-market-growth---technavio-301929309.html,BMY,0.043108,Neutral,0.0
"Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies - Merck, Amgen, Anaveon, Eisai, Regeneron, BMS, AstraZeneca, Seagen, Novartis, Eli Lilly and Company",20230724T210100,https://www.prnewswire.com/news-releases/cutaneous-melanoma-market-is-predicted-to-exhibit-remarkable-growth-predicts-delveinsight--key-companies---merck-amgen-anaveon-eisai-regeneron-bms-astrazeneca-seagen-novartis-eli-lilly-and-company-301883725.html,BMY,0.080638,Neutral,0.047754
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,BMY,0.020404,Neutral,0.078882
"With 14.1% CAGR, Monoclonal Antibody Therapy Market Size Worth USD 451.89 Billion by 2028",20230130T105418,https://www.benzinga.com/pressreleases/23/01/g30618366/with-14-1-cagr-monoclonal-antibody-therapy-market-size-worth-usd-451-89-billion-by-2028,BMY,0.035983,Bullish,0.353198
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors,20230104T213000,https://www.globenewswire.com/news-release/2023/01/04/2583300/0/en/MacroGenics-Announces-Appointment-of-Dr-Margaret-Liu-and-Meenu-Chhabra-Karson-to-Board-of-Directors.html,BMY,0.030918,Neutral,0.08884
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors - Macrogenics  ( NASDAQ:MGNX ) ,20230104T213000,https://www.benzinga.com/pressreleases/23/01/g30283535/macrogenics-announces-appointment-of-dr-margaret-liu-and-meenu-chhabra-karson-to-board-of-director,BMY,0.030602,Neutral,0.087755
"Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development",20220822T110000,https://www.benzinga.com/pressreleases/22/08/g28581547/bright-peak-therapeutics-announces-the-appointment-of-cancer-immunotherapy-leader-jon-wigginton-m-,BMY,0.046363,Neutral,-0.032716
"Stocks That Hit 52-Week Lows On Thursday - PRA Group  ( NASDAQ:PRAA ) , Perimeter Solutions  ( NYSE:PRM ) ",20231005T172202,https://www.benzinga.com/news/23/10/35111787/stocks-that-hit-52-week-lows-on-thursday,BMY,0.013047,Neutral,0.004444
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023,20240307T210700,https://www.prnewswire.com/news-releases/poseida-therapeutics-provides-updates-and-financial-results-for-the-fourth-quarter-and-full-year-2023-302083497.html,BMY,0.028188,Neutral,0.060752
"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio",20230925T210100,https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html,BMY,0.130723,Neutral,0.049466
Global Engineered T Cells Market Report 2022-2027: Increasing Demand for Innovative Biopharmaceutical Therapies & Recent Advances in CAR-T Cell Engineering Propelling Sector,20220811T124836,https://www.benzinga.com/pressreleases/22/08/g28454185/global-engineered-t-cells-market-report-2022-2027-increasing-demand-for-innovative-biopharmaceutic,BMY,0.039745,Neutral,0.0
5 NYSE Stocks To Watch And Buy: Here Are Fundamental And Technical Reasons Why,20220630T212500,https://www.investors.com/research/nyse-stocks-to-watch-buy/,BMY,0.110908,Neutral,-0.011156
"The Week Ahead In Biotech  ( June 5-11 ) : Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More",20220605T200922,https://www.benzinga.com/general/biotech/22/06/27558552/the-week-ahead-in-biotech-june-5-11-adcom-test-for-novavax-asco-presentations-enzo-biochem-earnin,BMY,0.121866,Neutral,0.080129
"Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday - Kohl's  ( NYSE:KSS ) ",20240828T141742,https://www.benzinga.com/news/24/08/40602596/kohls-posts-upbeat-q2-earnings-joins-box-waldencast-aerovironment-and-other-big-stocks-moving-higher,BMY,0.188193,Neutral,0.0
Anaveon appoints Dieter Weinand as Chair of its Board of Directors,20240730T060000,https://www.benzinga.com/pressreleases/24/07/g40028529/anaveon-appoints-dieter-weinand-as-chair-of-its-board-of-directors,BMY,0.090134,Neutral,0.038482
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? - Replimune Group  ( NASDAQ:REPL ) ,20240606T161620,https://www.benzinga.com/general/biotech/24/06/39211109/why-is-mid-cap-cancer-focused-replimune-stock-trading-higher-on-thursday,BMY,0.232439,Neutral,-0.123045
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology  ( ASCO )  Annual Meeting,20230603T181500,https://www.globenewswire.com/news-release/2023/06/03/2681534/0/en/Replimune-Presents-RP1-Data-from-the-IGNYTE-anti-PD1-Failed-Melanoma-Cohort-and-RP2-Data-in-Uveal-Melanoma-at-the-2023-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html,BMY,0.054857,Neutral,-0.003
Umoja Biopharma Appoints Dieter Weinand as the Chair of its Board of Directors,20221214T123000,https://www.benzinga.com/pressreleases/22/12/g30073538/umoja-biopharma-appoints-dieter-weinand-as-the-chair-of-its-board-of-directors,BMY,0.055751,Neutral,0.047895
"Why Replimune  ( REPL )  Shares Are Trading Higher Today - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ",20221207T150511,https://www.benzinga.com/general/biotech/22/12/29991461/replimune-shares-surge-after-early-data-from-pretreated-melanoma-patients,BMY,0.308891,Somewhat-Bearish,-0.187502
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update - Replimune Group  ( NASDAQ:REPL ) ,20221207T120000,https://www.benzinga.com/pressreleases/22/12/g29988444/replimune-announces-positive-initial-data-from-the-anti-pd1-failed-melanoma-cohort-of-the-ignyte-c,BMY,0.03443,Neutral,-0.076535
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update,20221207T120000,https://www.globenewswire.com/news-release/2022/12/07/2569129/0/en/Replimune-Announces-Positive-Initial-Data-from-the-Anti-PD1-Failed-Melanoma-Cohort-of-the-IGNYTE-Clinical-Trial-an-RP2-3-Program-Update.html,BMY,0.033751,Neutral,-0.019351
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma,20221207T113000,https://www.globenewswire.com/news-release/2022/12/07/2569082/0/en/Replimune-Enters-into-Clinical-Collaboration-Agreement-with-Roche-for-the-Development-of-RP3-In-Colorectal-Cancer-and-Hepatocellular-Carcinoma.html,BMY,0.039289,Neutral,0.130186
Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks,20220824T115800,https://www.fool.com/investing/2022/08/24/billionaires-are-scooping-up-these-2-beaten-down-b/,BMY,0.050254,Neutral,0.00702
Replimune To Present at the 2022 American Society of Clinical Oncology  ( ASCO )  Annual Meeting,20220526T211500,https://www.benzinga.com/pressreleases/22/05/g27432191/replimune-to-present-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting,BMY,0.061378,Neutral,0.009621
Replimune To Present at the 2022 American Society of Clinical Oncology  ( ASCO )  Annual Meeting,20220526T211500,https://www.globenewswire.com/news-release/2022/05/26/2451683/0/en/Replimune-To-Present-at-the-2022-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html,BMY,0.069164,Neutral,0.010004
"Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies",20220330T110000,https://www.benzinga.com/pressreleases/22/03/g26367562/replimune-provides-new-clinical-data-broad-program-update-and-future-development-strategy-for-its-,BMY,0.028664,Neutral,0.011514
"Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies",20220330T110000,https://www.globenewswire.com/news-release/2022/03/30/2412692/0/en/Replimune-Provides-New-Clinical-Data-Broad-Program-Update-and-Future-Development-Strategy-for-its-Tumor-Directed-Oncolytic-Immunotherapies.html,BMY,0.04356,Neutral,0.0116
"The Week Ahead In Biotech  ( March 27-April 2 ) : Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More",20220327T204003,https://www.benzinga.com/general/biotech/22/03/26313832/the-week-ahead-in-biotech-march-27-april-2-lipocine-akebia-merck-await-fda-verdicts-adcom-test-fo,BMY,0.074856,Neutral,-0.002725
"Global Precision Medicine Market Size Demonstrates Consistent Growth with a CAGR of 11.12%, with North America Taking a Leading Role - Illumina  ( NASDAQ:ILMN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",20231108T145000,https://www.benzinga.com/pressreleases/23/11/g35674541/global-precision-medicine-market-size-demonstrates-consistent-growth-with-a-cagr-of-11-12-with-nor,BMY,0.156461,Neutral,0.115839
Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight,20230821T210100,https://www.prnewswire.com/news-releases/medical-second-opinion-global-market-to-register-stunning-growth-at-a-cagr-of-17-by-2028--delveinsight-301905294.html,BMY,0.048671,Neutral,-0.031649
"Stocks Handle Huge Earnings, Fed, Jobs Report: Weekly Review",20240202T171500,https://www.investors.com/news/stock-market-handles-huge-earnings-week-fed-powell-jobs-report-weekly-review/,BMY,0.033236,Neutral,-0.133526
"SoFi, iRobot, Tesla, Archer Daniels, McGrath RentCorp, ZoomInfo, and More Stock Market Movers",20240129T092400,https://www.barrons.com/amp/articles/stock-market-movers-149f2d69,BMY,0.06211,Neutral,0.0
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20241127T130000,https://www.benzinga.com/pressreleases/24/11/g42212288/cytomx-therapeutics-to-present-at-the-36th-annual-piper-sandler-healthcare-conference,BMY,0.087824,Neutral,0.041182
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference,20241127T130000,https://www.globenewswire.com/news-release/2024/11/27/2988176/37704/en/CytomX-Therapeutics-to-Present-at-the-36th-Annual-Piper-Sandler-Healthcare-Conference.html,BMY,0.10607,Neutral,0.047068
"CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - CytomX Therapeutics  ( NASDAQ:CTMX ) ",20241031T120000,https://www.benzinga.com/pressreleases/24/10/g41650384/cytomx-therapeutics-to-report-third-quarter-2024-financial-results-on-november-7-2024,BMY,0.089462,Neutral,0.048799
"CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors",20240909T120000,https://www.globenewswire.com/news-release/2024/09/09/2942754/37704/en/CytomX-Therapeutics-Announces-First-Patient-Dosed-with-CX-801-a-Dually-Masked-Interferon-Alpha-2b-PROBODY-in-a-Phase-1-Study-in-Patients-with-Solid-Tumors.html,BMY,0.039483,Neutral,0.047495
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference,20240618T120000,https://www.globenewswire.com/news-release/2024/06/18/2900339/37704/en/CytomX-Therapeutics-to-Present-at-the-H-C-Wainwright-2nd-Annual-Immune-Cell-Engager-Virtual-Conference.html,BMY,0.109956,Neutral,0.055734
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240617T201500,https://www.benzinga.com/pressreleases/24/06/g39366109/cytomx-therapeutics-promotes-chris-ogden-to-chief-financial-officer,BMY,0.034087,Neutral,0.04386
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer,20240617T201500,https://www.globenewswire.com/news-release/2024/06/17/2900015/37704/en/CytomX-Therapeutics-Promotes-Chris-Ogden-to-Chief-Financial-Officer.html,BMY,0.036091,Neutral,0.046131
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference,20240522T200500,https://www.globenewswire.com/news-release/2024/05/22/2886834/37704/en/CytomX-Therapeutics-to-Present-at-the-Jefferies-Global-Healthcare-Conference.html,BMY,0.113597,Neutral,0.056493
CytomX Therapeutics Announces New Employment Inducement Grants,20240516T201500,https://www.globenewswire.com/news-release/2024/05/16/2883880/37704/en/CytomX-Therapeutics-Announces-New-Employment-Inducement-Grants.html,BMY,0.098255,Neutral,0.051259
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240508T201000,https://www.benzinga.com/pressreleases/24/05/g38712713/cytomx-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-update,BMY,0.046154,Neutral,0.071763
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA®  ( pembrolizumab ) ,20240507T201500,https://www.globenewswire.com/news-release/2024/05/07/2877258/37704/en/CytomX-Therapeutics-Announces-Clinical-Collaboration-with-Merck-to-Evaluate-CX-801-in-Combination-with-KEYTRUDA-pembrolizumab.html,BMY,0.032961,Neutral,0.046708
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific  ( TCB )  Collaboration with Astellas,20240403T120000,https://www.globenewswire.com/news-release/2024/04/03/2856845/37704/en/CytomX-Therapeutics-Announces-Nomination-of-Second-Clinical-Candidate-in-Broad-PROBODY-T-Cell-Engaging-Bispecific-TCB-Collaboration-with-Astellas.html,BMY,0.039811,Neutral,0.04956
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240311T201000,https://www.benzinga.com/pressreleases/24/03/g37598795/cytomx-therapeutics-reports-2023-financial-results-and-provides-business-update,BMY,0.110826,Neutral,0.062567
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update,20240311T201000,https://www.globenewswire.com/news-release/2024/03/11/2844158/37704/en/CytomX-Therapeutics-Reports-2023-Financial-Results-and-Provides-Business-Update.html,BMY,0.111193,Neutral,0.045954
CytomX  ( CTMX )  to Report Q4 Earnings: Here's What to Expect,20240227T165200,https://www.zacks.com/stock/news/2232603/cytomx-ctmx-to-report-q4-earnings-heres-what-to-expect,BMY,0.288044,Neutral,-0.013155
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240112T130000,https://www.benzinga.com/pressreleases/24/01/g36609305/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-conference,BMY,0.188928,Neutral,0.033129
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference,20240112T130000,https://www.globenewswire.com/news-release/2024/01/12/2808578/37704/en/CytomX-Therapeutics-to-Present-at-the-B-Riley-Securities-Virtual-Annual-Oncology-Conference.html,BMY,0.209365,Neutral,0.037617
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20240104T130000,https://www.benzinga.com/pressreleases/24/01/g36488030/cytomx-therapeutics-outlines-2024-company-priorities-and-milestones,BMY,0.180325,Neutral,0.070017
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones,20240104T130000,https://www.globenewswire.com/news-release/2024/01/04/2803919/37704/en/CytomX-Therapeutics-Outlines-2024-Company-Priorities-and-Milestones.html,BMY,0.166679,Neutral,0.060408
CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference,20231221T130000,https://www.globenewswire.com/news-release/2023/12/21/2799945/37704/en/CytomX-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,BMY,0.201523,Neutral,-0.037842
CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20231221T130000,https://www.benzinga.com/pressreleases/23/12/g36341721/cytomx-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference,BMY,0.186738,Neutral,-0.0341
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update,20231107T211500,https://www.globenewswire.com/news-release/2023/11/07/2775653/37704/en/CytomX-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,BMY,0.089729,Neutral,0.013733
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20231107T211500,https://www.benzinga.com/pressreleases/23/11/g35658764/cytomx-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-update,BMY,0.104911,Neutral,0.04202
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20231030T120000,https://www.benzinga.com/pressreleases/23/10/g35487786/cytomx-therapeutics-to-present-preclinical-data-for-conditionally-activated-interferon-alpha-2b-at,BMY,0.087027,Neutral,-0.009532
CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference,20231018T203000,https://www.globenewswire.com/news-release/2023/10/18/2762767/37704/en/CytomX-Therapeutics-Presents-Preclinical-Profile-of-EpCAM-directed-Antibody-Drug-Conjugate-CX-2051-at-2023-World-ADC-Conference.html,BMY,0.073773,Neutral,-0.00924
"Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period  ( 2023-2032 ) , Examines DelveInsight | Key Companies to Watch - Roche, AbbVie, AstraZeneca, BeiGene, GlaxoSmithKline, Genentech, Eli Lilly, Novartis",20230906T210100,https://www.prnewswire.com/news-releases/triple-negative-breast-cancer-market-to-accelerate-substantially-during-the-forecast-period-20232032-examines-delveinsight--key-companies-to-watch---roche-abbvie-astrazeneca-beigene-glaxosmithkline-genentech-eli-lilly--301918858.html,BMY,0.022494,Neutral,0.023078
CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20230810T200500,https://www.benzinga.com/pressreleases/23/08/g33723142/cytomx-therapeutics-to-present-at-the-h-c-wainwright-immune-cell-engager-virtual-conference,BMY,0.183895,Neutral,-0.001551
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update,20230808T201500,https://www.globenewswire.com/news-release/2023/08/08/2721181/37704/en/CytomX-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,BMY,0.05383,Neutral,0.008003
Why CytomX Therapeutics  ( CTMX )  Shares Are Falling Today - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20230328T153514,https://www.benzinga.com/general/biotech/23/03/31531824/abbvie-walks-away-from-cytomx-partnership-but-garnering-attention-of-big-pharma-partners,BMY,0.277433,Neutral,0.0
CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update,20230327T201500,https://www.globenewswire.com/news-release/2023/03/27/2635245/37704/en/CytomX-Therapeutics-Reports-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html,BMY,0.063341,Neutral,0.01913
"CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023 - CytomX Therapeutics  ( NASDAQ:CTMX ) ",20230322T232333,https://www.benzinga.com/pressreleases/23/03/g31466980/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-27-2023,BMY,0.172097,Neutral,-0.036731
"CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023",20230322T232300,https://www.globenewswire.com/news-release/2023/03/22/2632792/37704/en/CytomX-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-March-27-2023.html,BMY,0.184598,Neutral,-0.041876
CytomX Therapeutics to Present at Upcoming March Investor Conferences - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20230228T210500,https://www.benzinga.com/pressreleases/23/02/g31103016/cytomx-therapeutics-to-present-at-upcoming-march-investor-conferences,BMY,0.165031,Neutral,-0.037087
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific  ( TCB )  Collaboration with Astellas,20230126T120000,https://www.globenewswire.com/news-release/2023/01/26/2595893/37704/en/CytomX-Therapeutics-Announces-Milestone-Achievement-in-Probody-T-Cell-Engaging-Bispecific-TCB-Collaboration-with-Astellas.html,BMY,0.068209,Neutral,-0.02641
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference,20230117T210500,https://www.benzinga.com/pressreleases/23/01/g30450762/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-investor-conferen,BMY,0.157483,Neutral,-0.053591
"CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics - CytomX Therapeutics  ( NASDAQ:CTMX ) , Moderna  ( NASDAQ:MRNA ) ",20230105T210500,https://www.benzinga.com/pressreleases/23/01/g30301606/cytomx-and-moderna-announce-strategic-research-collaboration-for-mrna-based-conditionally-activate,BMY,0.04476,Neutral,-0.026954
"CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023",20221222T220000,https://www.globenewswire.com/news-release/2022/12/22/2578939/37704/en/CytomX-Therapeutics-to-Outline-2023-Company-Priorities-and-Provide-Pipeline-Update-on-January-5-2023.html,BMY,0.17715,Neutral,-0.042279
CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference,20221220T220000,https://www.globenewswire.com/news-release/2022/12/20/2577524/37704/en/CytomX-Therapeutics-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html,BMY,0.163909,Neutral,-0.059659
CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20221220T220000,https://www.benzinga.com/pressreleases/22/12/g30153373/cytomx-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference,BMY,0.153961,Neutral,-0.054343
CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine  ( CX-2009 )  in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20221207T213000,https://www.benzinga.com/pressreleases/22/12/g29999143/cytomx-therapeutics-to-present-phase-2-data-for-praluzatamab-ravtansine-cx-2009-in-patients-with-a,BMY,0.120733,Neutral,-0.047412
CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine  ( CX-2009 )  in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium,20221207T213000,https://www.globenewswire.com/news-release/2022/12/07/2569745/37704/en/CytomX-Therapeutics-to-Present-Phase-2-Data-for-Praluzatamab-Ravtansine-CX-2009-in-Patients-with-Advanced-Breast-Cancer-at-the-San-Antonio-Breast-Cancer-Symposium.html,BMY,0.069596,Neutral,-0.041707
CytomX  ( CTMX )  Stock Surges on Oncology Deal With Regeneron,20221118T181800,https://www.zacks.com/stock/news/2020092/cytomx-ctmx-stock-surges-on-oncology-deal-with-regeneron,BMY,0.220809,Neutral,0.0
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b  ( CX-801 )  at the SITC 2022 Annual Meeting,20221107T211500,https://www.globenewswire.com/news-release/2022/11/07/2550277/37704/en/CytomX-Therapeutics-to-Present-Preclinical-Data-for-Conditionally-Activated-Interferon-Alpha-2b-CX-801-at-the-SITC-2022-Annual-Meeting.html,BMY,0.07031,Neutral,-0.043812
CytomX Therapeutics to Present at Upcoming November Investor Conferences,20221102T201500,https://www.globenewswire.com/news-release/2022/11/02/2547066/37704/en/CytomX-Therapeutics-to-Present-at-Upcoming-November-Investor-Conferences.html,BMY,0.166743,Neutral,-0.06039
CytomX Therapeutics to Present at Upcoming November Investor Conferences - CytomX Therapeutics  ( NASDAQ:CTMX ) ,20221102T201500,https://www.benzinga.com/pressreleases/22/11/g29532629/cytomx-therapeutics-to-present-at-upcoming-november-investor-conferences,BMY,0.143415,Neutral,-0.052044
CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249,20220912T120000,https://www.globenewswire.com/news-release/2022/09/12/2513952/37704/en/CytomX-Therapeutics-Announces-Phase-1-Data-Update-for-anti-CTLA-4-Probody-Therapeutic-BMS-986249.html,BMY,0.114682,Neutral,-0.055283
CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate  ( ADC )  Programs Including Next Generation EpCAM-Targeting CX-2051,20220907T220500,https://www.globenewswire.com/news-release/2022/09/07/2512047/37704/en/CytomX-Therapeutics-Presents-Overview-of-Conditionally-Activated-Antibody-Drug-Conjugate-ADC-Programs-Including-Next-Generation-EpCAM-Targeting-CX-2051.html,BMY,0.059415,Neutral,-0.056235
CytomX Therapeutics  ( CTMX )  Q2 2022 Earnings Call Transcript,20220805T123040,https://www.fool.com/earnings/call-transcripts/2022/08/05/cytomx-therapeutics-ctmx-q2-2022-earnings-call-tra/,BMY,0.023002,Neutral,0.094858
CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update,20220804T201500,https://www.globenewswire.com/news-release/2022/08/04/2492842/37704/en/CytomX-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Provides-Business-Update.html,BMY,0.098416,Neutral,0.0
CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences,20220803T120000,https://www.globenewswire.com/news-release/2022/08/03/2491316/37704/en/CytomX-Therapeutics-to-Present-at-Upcoming-Virtual-August-Investor-Conferences.html,BMY,0.19117,Neutral,-0.088654
CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer,20220706T200500,https://www.globenewswire.com/news-release/2022/07/06/2475436/37704/en/CytomX-Therapeutics-Announces-Phase-2-Results-for-Praluzatamab-Ravtansine-in-Breast-Cancer.html,BMY,0.041545,Somewhat-Bullish,0.290945
CytomX Therapeutics  ( CTMX )  Q1 2022 Earnings Call Transcript,20220507T023041,https://www.fool.com/earnings/call-transcripts/2022/05/06/cytomx-therapeutics-ctmx-q1-2022-earnings-call-tra/,BMY,0.014108,Neutral,0.061269
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update,20220505T201500,https://www.globenewswire.com/news-release/2022/05/05/2437387/37704/en/CytomX-Therapeutics-Reports-First-Quarter-2022-Financial-Results-and-Provides-Business-Update.html,BMY,0.081097,Somewhat-Bullish,0.185616
"CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022",20220428T120000,https://www.globenewswire.com/news-release/2022/04/28/2431297/37704/en/CytomX-Therapeutics-to-Report-First-Quarter-2022-Financial-Results-on-May-5-2022.html,BMY,0.174398,Somewhat-Bullish,0.273357
"CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors",20220414T201500,https://www.benzinga.com/pressreleases/22/04/g26646216/cytomx-therapeutics-announces-retirement-of-john-a-scarlett-m-d-from-board-of-directors,BMY,0.130748,Somewhat-Bullish,0.20252
"CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors",20220414T201500,https://www.globenewswire.com/news-release/2022/04/14/2423090/37704/en/CytomX-Therapeutics-Announces-Retirement-of-John-A-Scarlett-M-D-from-Board-of-Directors.html,BMY,0.071209,Somewhat-Bullish,0.273357
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors,20220323T201500,https://www.benzinga.com/pressreleases/22/03/g26266130/cytomx-therapeutics-announces-retirement-of-frederick-w-gluck-from-board-of-directors,BMY,0.123748,Somewhat-Bullish,0.20252
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors,20220323T201500,https://www.globenewswire.com/news-release/2022/03/23/2408989/37704/en/CytomX-Therapeutics-Announces-Retirement-of-Frederick-W-Gluck-from-Board-of-Directors.html,BMY,0.137318,Somewhat-Bullish,0.273357
Corcept Submits Application for Another Cushing's Syndrome Drug,20241231T184000,https://www.zacks.com/stock/news/2390198/corcept-submits-application-for-another-cushings-syndrome-drug,BMY,0.156461,Neutral,0.0
"The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight",20231009T210100,https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-factor-based-bleeding-disorders-hemophilia-a-hemophilia-b-and-von-willebrand-disease--key-analysis-by-delveinsight-301950491.html,BMY,0.054483,Neutral,0.032874
RIGL: 1 Pharma Stock to Buy for Under $1 This December,20221212T130959,https://stocknews.com/news/rigl-nvo-pfe-bmy-1-pharma-stock-to-buy-for-under-1-this-december/,BMY,0.136499,Neutral,0.097382
"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Key Companies - Bristol Myers Squibb, Innate Pharma, Kymera Therapeutics, EUSA Pharma, Abcuro, Dren Bio, Novotech",20231016T210100,https://www.prnewswire.com/news-releases/large-granular-lymphocyte-leukemia-market-is-projected-to-grow-during-the-study-period-20192032-assesses-delveinsight--key-companies---bristol-myers-squibb-innate-pharma-kymera-therapeutics-eusa-pharma-abcuro-dren-bio-n-301957023.html,BMY,0.025845,Neutral,-0.026539
LAVA Therapeutics Announces Two Appointments to its Board of Directors,20220615T110000,https://www.globenewswire.com/news-release/2022/06/15/2462948/0/en/LAVA-Therapeutics-Announces-Two-Appointments-to-its-Board-of-Directors.html,BMY,0.038059,Neutral,0.019888
LAVA Therapeutics Announces Two Appointments to its Board of Directors,20220615T110000,https://www.benzinga.com/pressreleases/22/06/g27715260/lava-therapeutics-announces-two-appointments-to-its-board-of-directors,BMY,0.036694,Neutral,0.019888
"The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More",20220512T124254,https://www.benzinga.com/general/biotech/22/05/27161064/the-daily-biotech-pulse-bristol-myers-bridgebio-ink-oncology-pact-fda-nod-for-lava-therapeutics-b,BMY,0.080525,Neutral,0.002467
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors,20241213T120000,https://www.globenewswire.com/news-release/2024/12/13/2996712/0/en/Monte-Rosa-Therapeutics-Appoints-Dr-Eric-A-Hughes-to-Board-of-Directors.html,BMY,0.062926,Neutral,-0.033021
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Monte Rosa Therapeutics  ( NASDAQ:GLUE ) ,20241213T120000,https://www.benzinga.com/pressreleases/24/12/g42481101/monte-rosa-therapeutics-appoints-dr-eric-a-hughes-to-board-of-directors,BMY,0.058472,Neutral,-0.032999
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20240711T213100,https://www.prnewswire.com/news-releases/molecular-glues-clinical-trial-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-302194515.html,BMY,0.099373,Neutral,-0.001064
"3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street",20240116T140000,https://www.fool.com/investing/2024/01/16/3-incredible-growth-stocks-that-could-soar-in-2024/,BMY,0.058047,Neutral,-0.027038
"RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships",20240610T123000,https://www.globenewswire.com/news-release/2024/06/10/2895991/0/en/RenovoRx-Appoints-Ryan-Witt-as-Senior-Vice-President-Head-of-Corporate-Strategy-and-Partnerships.html,BMY,0.025985,Neutral,0.100794
"RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships - Immix Biopharma  ( NASDAQ:IMMX ) , RenovoRx  ( NASDAQ:RNXT ) ",20240610T123000,https://www.benzinga.com/pressreleases/24/06/g39249080/renovorx-appoints-ryan-witt-as-senior-vice-president-head-of-corporate-strategy-and-partnerships,BMY,0.025139,Neutral,0.100354
"Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells",20230331T120000,https://www.globenewswire.com/news-release/2023/03/31/2638581/0/en/Nexcella-an-Immix-Biopharma-Subsidiary-Announces-2023-Haematologica-Editorial-Highlighting-NXC-201-Efficacy-In-The-Context-of-U-S-Food-And-Drug-Administration-Approved-BCMA-CAR-T-C.html,BMY,0.025845,Neutral,0.055979
Calif. Pharmaceutical Companies AbbVie And Bristol Myers Lay Off 360-Here Are The Major U.S. Layoffs This Summer,20220917T171330,https://www.forbes.com/sites/brianbushard/2022/09/17/calif-pharmaceutical-companies-abbvie-and-bristol-myers-lay-off-360-here-are-the-major-us-layoffs-this-summer/,BMY,0.027699,Neutral,-0.055408
